Stock Details
ALPMF is Astellas Pharma Inc.'s stock. Stock exchange Other OTC (Currency USD). Average price in 50 days is 14.57$. Average daily volumn in 3 months 2.04k. Market cap 21.90B



Stock symbol : ALPMF. Exchange : Other OTC. Currency : USD
Lastest price : 12.77$. Total volume : 42.30k. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Astellas Pharma Inc. (ALPMF)
Last Price
12.77$
Change
0.00
Volume
42.30k

Previous Close12.77
Open13.10
Day Range12.77-12.77
Bid0.00 x N/A
Ask0.00 x N/A
Volume42.3k
Average Volume2.04k
Market Cap21.9B
BetaN/A
52 Week Range12.77-17.95
Trailing P/E27.76
Foward P/EN/A
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Astellas Pharma Inc.'s financial reports the company's revenue in 2022 were 1.3T an increase(0%) over the years 2021 revenue that were of 1.25T. In 2022 the company's total earnings were 124.09B while total earnings in 2021 were 120.59B( +3.33%).


Loading ...



Organization

Market Cap:
21.90B
Revenue:
1.3T
Total Assets:
2.33T
Total Cash:
315.99B


News about "Astellas Pharma Inc."

Astellas : EMA Accepts Marketing Authorization Application For Fezolinetant

Source from : Business Insider - 1 days ago

Astellas Pharma Inc. said that the European Medicines Agency or EMA has accepted for regulatory review the company's marketing ...See details»


Astellas Pharma Inc. ADR

Source from : Wall Street Journal - 17 days ago

1 Day ALPMY -1.91% DJIA -3.54% S&P 500 -3.90% Health Care/Life Sciences -0.27% Kenji Yasukawa President, CEO & Representative Director Astellas Pharma SpA, Astellas Pharma, Inc. Naoki Okamura ...See details»


European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant

Source from : Business Insider - 1 days ago

If authorized by the European Commission, fezolinetant would be a nonhormonal treatment for moderate to severe vasomotor symptoms associated with ...See details»


Astellas confirms US District Court decision for an interim injunction against Hospira for Lexiscan

Source from : Pharmabiz - 4 days ago

Astellas Pharma Inc. confirms the US District Court for the District of Delawareโ€™s order granting an interim injunction enjoining Hospira from launching its generic version of Lexiscan until October 5 ...See details»


Treatment for hot flushes and night sweats accepted for regulatory review by EMA

Source from : labiotech - 1 days ago

A treatment for moderate to severe vasomotor symptoms (VMS) has been accepted by the European Medicines Agency (EMA) for regulatory review. Astellas Pharma Inc., submitted a marketing authorization ...See details»


EMA accepts Astellasโ€™ filing for fezolinetant

Source from : The Pharma Letter - 1 days ago

Supporting the filing are results fromโ€ฆ โ€ข All the news that moves the needle in pharma and biotech. โ€ข Exclusive features, podcasts, interviews, data analyses and commentary from our global network of ...See details»


Mixed news for Astellas regarding Lexiscan patent dispute

Source from : The Pharma Letter - 5 days ago

Astellas Pharma (TYO: 4503) saw its share gain 1.6% in early trading, though they drifted back, as it revealed it has won a reprieve in its patent dispute with generics and biosimilar injectables ...See details»


Astellas facing generics to big-selling Lexiscan product in US

Source from : pharmaphorum - 5 days ago

Lexiscan was originally developed by CV Therapeutics, which licensed rights to the drug to Astellas shortly before the Japanese pharma launched a hostile bid for the company โ€“ thwarted when it ...See details»


European Medicines Agency Accepts Astellas'...

Source from : Benzinga.com - 1 days ago

If authorized by the European Commission, fezolinetant would be a nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause TOKYO, Sept. /PRNewswire/ -- Astellas Pharma ...See details»


Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China

Source from : Yahoo Finance - 26 days ago

4, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced topline results from the Phase 3 MOONLIGHT 3โ„ข clinical trial in ...See details»


usfda-approves-lupins-extended-release-tablets-for-overactive-bladder-image

USFDA approves Lupinโ€™s extended release tablets for overactive bladder

Source from : The Financial Express on MSN - 2 days ago

Mirabegron is indicated to treat overactive bladder or neurogenic detrusor overactivity but does not cure these conditions.See details»


Seagen, Astellas, Merck: EV-103 Results Support Investigation Of Enfortumab Vedotin, Pembrolizumab

Source from : Nasdaq - 19 days ago

(RTTNews) - Seagen Inc. (SGEN), Astellas Pharma Inc. and Merck (MRK) reported results from the phase 1b/2 EV-103 clinical trial Cohort K investigating PADCEV, or enfortumab vedotin-ejfv ...See details»


lupin-bags-usfda-approval-for-mirabegron-er-tablets-to-treat-overactive-bladder-image

Lupin bags USFDA approval for Mirabegron ER tablets to treat overactive bladder

Source from : Daily - 1 days ago

Mirabegron is indicated for treating the overactive bladder or neurogenic detrusor overactivity but does not cure these conditions. Read also: Lupin unveils Sodium Sulfate, Potassium Sulfate and ...See details»


Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts

Source from : Yahoo Finance - 11 days ago

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators TOKYO and SAN FRANCISCO, Sept. 19, 2022 /PRNewswire ...See details»